 MEDICLINIC ANNUAL REPORT 2017 2 PERFORMANCE HIGHLIGHTS
PERFORMANCE HIGHLIGHTS
0
50
100
150
200
250
0
100
200
300
400
500
600
0
50
100
150
200
250
300
350
400
0
500
1000
1500
2000
2500
3000
*  IFRS measure
**  Non-IFRS measure
See the reconciliations between the statutory and underlying (non-IFRS) measures on pages 16 to 17. AR
REVENUE (£’M)*
2013
2014
2015
2016
2017
1 818
1 892
1 977
2 107
2 749
2013
2014
2015
2016
2017
OPERATING PROFIT (£’M)*
307
342
345
288
362
2013
2014
2015
2016
2017
UNDERLYING EBITDA (£’M)** 
501
401
403
428
501
2013
2014
2015
2016
2017
UNDERLYING EARNINGS (£’M)** 
143
193
219
220
189
STRATEGIC REPORT
• 
Revenue up 30% to £2 749m; up 15% compared to pro forma FY16 revenue including Al Noor (£2 391m)
• 
Underlying EBITDA up 17% to £501m; underlying EBITDA margin decreased to 18.2% from 20.4%
• 
Operating profit up 26% to £362m
• 
Underlying earnings per share down 19% to 29.8 pence
• 
In constant currency, revenue and underlying EBITDA increased by 15% and 3% respectively
• 
Cash flow conversion at 101% of underlying EBITDA
• 
T otal dividend of 7.90 pence per share; in line with dividend policy
• 
Hirslanden revenue up 3% to CHF1 704m; underlying EBITDA up 5% to CHF340m;  
underlying EBITDA margin of 20.0%
• 
Southern Africa revenue up 7% to ZAR14 367m; underlying EBITDA up 6% to ZAR3 049m;  
underlying EBITDA margin of 21.2%
• 
Middle East revenue up 72% to AED3 109m; revenue down 8% versus pro forma for the Al Noor 
combination; underlying EBITDA down 5% to AED364m; underlying EBITDA margin of 11.7% 
GROUP FINANCIAL RESULTS
OPERATING PERFORMANCE MEDICLINIC ANNUAL REPORT 2017 3 PERFORMANCE HIGHLIGHTS
KEY PERFORMANCE INDICATORS
FINANCIAL 2017 2016
%
change
Revenue £'m 2 749 2 107 30%
EBITDA
1
£'m 509 382 33%
Underlying EBITDA
1
£'m 501 428 17%
Operating profit £'m 362 288 26%
Earnings
2
£'m 229 177 29%
Underlying earnings
1
£'m 220 219 0%
Basic earnings per share pence 31.0 29.6 5%
Underlying basic earnings per share
1
pence 29.8 36.7 (19%)
Total dividend per share
3
pence 7.90 7.90 –
Net debt at the year end £'m 1 669 1 536 9%
Capital expenditure on projects, new equipment  
and replacement of equipment £'m 249 186 34%
Southern Africa £'m 72 52 38%
Switzerland £'m 127 98 30%
United Arab Emirates £'m 50 36 39%
Notes
1
  The Group uses underlying income statement reporting as non-IFRS measures in evaluating performance and as a 
method to provide shareholders with clear and consistent reporting. See the reconciliations between the statutory and the  
non-IFRS measures in the Financial Review on pages 16 to 17.
2
 Earnings refer to profit attributable to equity holders.
3
  The total dividend per share for the year ended 31 March 2017 in British pound comprises the proposed final dividend  
of 4.70 pence per share (2016: 5.24 pence) and the interim dividend of 3.20 pence per share, paid in December 2016  
(2016: 2.66 pence).
Group results are subject to movements in foreign currency exchange rates. Refer to page 15 for exchange 
rates used to convert the operating platforms’ results to pound sterling.
OPERATIONAL 2017 2016
Number of hospitals in operation 74 73
Southern Africa 52 52
Switzerland 16 16
United Arab Emirates 6 5
Number of clinics in operation 37 45
Southern Africa 2 2
Switzerland 4 4
United Arab Emirates 31 39
Number of licensed/registered beds (including day facility beds) 10 486 10 415
Southern Africa 8 095 8 017
Switzerland 1 677 1 677
United Arab Emirates 714 721
Number of licensed/registered theatres (including day facility theatres) 400 387
Southern Africa 278 270
Switzerland 97 92
United Arab Emirates 25 25
AR
AR MEDICLINIC ANNUAL REPORT 2017 4 PERFORMANCE HIGHLIGHTS
KEY PERFORMANCE INDICATORS (continued)
SOCIAL, ENVIRONMENTAL AND OTHER 2017 2016
Included in RobecoSAM Dow Jones Sustainability Index Yes Yes
Number of employees 32 625 32 884
Southern Africa 16 848 16 832
Switzerland 9 402 9 120 
United Arab Emirates 6 375 6 932 
Staff turnover rate
Southern Africa 6.3% 6.8% 
Switzerland 7.2% 5.2% 
United Arab Emirates 19.8% 12.4% 
Training spend as approximate percentage of payroll
Southern Africa 3.2% 3.6% 
Switzerland 4.8% 5.0%
United Arab Emirates 0.1% 0.3% 
Corporate social investment spend
Southern Africa* R'm 12.3 11.8
Switzerland CHF'm 2.5 2.5 
United Arab Emirates AED'm 1.0 0.8 
Transformation (South Africa only)
Percentage black employees 71.2% 70.5% 
Percentage black management employees 27.7% 25.7% 
Total energy usage (gigajoules/bed day) 1.792 1.652
Southern Africa** 0.327 0.333 
Switzerland (per calendar year) 0.474 0.477 
United Arab Emirates (hospitals only)** 0.991 0.842 
Ranking in CDP Climate Disclosure Leadership Index  
(per calendar year)**
Included in
the Global
A List for
perform-
ance
(CDP 2017)
Included in
the Global
A List for
perform-
ance
(CDP 2016)
Notes
*  The corporate social investment of Mediclinic Southern Africa excludes the significant financial support to academic 
institutions in the amount of R9.7m (2016: R8.0m) during the year.
**  The environmental data of Mediclinic Southern Africa and Mediclinic Middle East is for the 2016 calendar year, while the 
comparative data is for the financial year ended 31 March 2016. The environmental data relating to Hirslanden was also 
reported on a calendar year basis in previous reports.
SDR
